Streetbeat News

Price Targets

TXG

In the last three months, 4 analysts have updated their ratings on 10x Genomics (NASDAQ:TXG), showing a mix of bullish and somewhat bullish perspectives. The average 12-month price target is now $54.5, down from $57.00, indicating a 4.39% decrease. The company has seen a revenue growth of 17.76% as of December 31, 2023, but struggles with profitability and efficiency, as indicated by its net margin of -26.61%, ROE of -6.59%, and ROA of -5.12%. Its debt-to-equity ratio is 0.13, suggesting a sound financial structure.

Portfolio Pulse from Benzinga Insights

April 18, 2024 | 5:00 pm

WDC

Morgan Stanley analyst Joseph Moore has maintained an Overweight rating on Western Digital (NASDAQ:WDC) and increased the price target from $73 to $83.

Portfolio Pulse from Benzinga Newsdesk

April 18, 2024 | 4:56 pm

PACB

Bernstein analyst Eve Burstein maintains an Outperform rating on Pacific Biosciences (PACB) but lowers the price target from $9 to $2.5.

Portfolio Pulse from Benzinga Newsdesk

April 18, 2024 | 4:56 pm

TS

Morgan Stanley analyst Connor Lynagh downgraded Tenaris (NYSE:TS) from Overweight to Underweight and set a new price target of $40. This adjustment reflects a more cautious outlook on the company's stock.

Portfolio Pulse from Benzinga Newsdesk

April 18, 2024 | 4:54 pm

COIN

Bernstein analyst Harshita Rawat maintains a Market Perform rating on Coinbase Global (COIN) and raises the price target from $80 to $200.

Portfolio Pulse from Benzinga Newsdesk

April 18, 2024 | 4:53 pm

LVS

Deutsche Bank analyst Carlo Santarelli maintains a Buy rating on Las Vegas Sands (LVS) but lowers the price target from $66 to $62.

Portfolio Pulse from Benzinga Newsdesk

April 18, 2024 | 4:50 pm

RIVN

Needham analyst Chris Pierce maintains a Buy rating on Rivian Automotive (NASDAQ:RIVN) but lowers the price target from $18 to $13, citing concerns over electric vehicle demand but noting better than feared demand for the R1S. Pierce updates delivery estimates for Rivian, with figures for 2024 and 2025 below consensus but 2026 and 2027 above. The R2 vehicle launch is seen as a long-term positive, though not a near-term catalyst. Rivian's strategy includes reducing planned capex by delaying the build-out of its Georgia plant. The analyst's bull case for Rivian is a $24 price target, with a bear case at $7.50. Rivian shares are up 2% to $8.93, with a 52-week range of $8.26 to $28.06, and a year-to-date decrease of 63% in 2024.

Portfolio Pulse from Chris Katje

April 18, 2024 | 4:49 pm

KHC

Deutsche Bank analyst Stephen Powers maintains a Buy rating on Kraft Heinz (NASDAQ:KHC) and raises the price target from $42 to $43.

Portfolio Pulse from Benzinga Newsdesk

April 18, 2024 | 4:48 pm

JD

Morgan Stanley analyst Eddy Wang has reiterated an Equal-Weight rating on JD.com (NASDAQ:JD) and maintained a $27 price target on the stock.

Portfolio Pulse from Benzinga Newsdesk

April 18, 2024 | 4:47 pm

HTZ

Deutsche Bank analyst Chris Woronka has maintained a Hold rating on Hertz Global Holdings (NASDAQ:HTZ) but lowered the price target from $10 to $6.

Portfolio Pulse from Benzinga Newsdesk

April 18, 2024 | 4:40 pm